The classic view is that unliganded GRα resides in the cytoplasm, relocates to the nucleus after ligand binding, and then associates with a specific DNA sequence, namely a glucocorticoid response element (GRE), to activate a specific gene as a homodimer. It is still a puzzle, however, whether GRα forms the homodimer in the cytoplasm or in the nucleus before DNA binding or after that. To quantify the homodimerization of GRα, we constructed the spectrally different fluorescent protein tagged hGRα and applied fluorescence cross-correlation spectroscopy. First, the dissociation constant (K d ) of mCherry 2 -fused hGRα or EGFP-fused hGRα was determined in vitro. Then, K d of wild-type hGRα was found to be 3.00 μM in the nucleus, which was higher than that in vitro. K d of a DNA-bindingdeficient mutant was 3.51 μM in the nucleus. This similarity indicated that GRα homodimerization was not necessary for DNA binding but could take place on GRE by means of GRE as a scaffold. Moreover, cytoplasmic homodimerization was also observed using GRα mutated in the nuclear localization signal. These findings support the existence of a dynamic monomer pathway and regulation of GRα function both in the cytoplasm and nucleus.
Understanding the interactions and dynamic properties of biomolecules in living cells is of paramount importance in life sciences. Glucocorticoid receptor α (GRα) is a natural-steroid-and synthetic-steroid-regulated transcription factor, a member of the nuclear receptor superfamily that regulates a variety of physiological functions via several mechanisms. It is widely thought that unliganded GRα is primarily located in the cytoplasm as part of a multiprotein complex with chaperones and immunophilins [1] [2] [3] . After ligand binding, GRα is translocated to the nucleus, where it works either as a homodimer that binds to positive or negative glucocorticoid response elements (GRE) located in the promoter regions of target genes, or as a monomer that cooperates with other transcription factors to induce transcription [4] [5] [6] [7] . In addition, the homodimer of GRα can act as a repressor in association with a negative GRE, and as a monomer can tether other transcription factors such as NF-κB 8, 9 . A number of in vitro studies suggest that GRα homodimerizes after ligand binding [10] [11] [12] [13] [14] . It has been demonstrated that two molecules of the DNA-binding domain of GRα bind to a GRE in a cooperative manner, where binding of the first molecule accelerates binding of the second molecule 10, 15, 16 . It was also reported, however, that the preformed homodimer of the GRα preferentially binds to the GRE rather than sequential binding of the monomer [17] [18] [19] [20] [21] . It is still unclear whether binding of GRα to the GRE is followed by simple sequential or cooperative binding of the second monomer. Several recent studies have shown homodimerization of GRα in vivo 17, 20, 22 . Moreover, GRα homodimerization in the cytoplasm before translocation to the nucleus has been reported 17, 20, 23 . However, it FCCS analysis of WT hGRα in the nucleus and cytoplasm. To study the GRα homodimerization in living cells, FCCS was performed in living U2OS cells. The cells were transiently cotransfected with plasmid constructs expressing EGFP-hGRα and mCherry 2 -hGRα ( Fig. S1A and B) . The fusion proteins mCherry 2 -hGRα and EGFP-hGRα were initially localized to the cytoplasm in the absence of Dex ( Fig. 3(d) , inset), but after the addition of Dex, both mCherry 2 -hGRα and EGFP-hGRα were translocated to the nucleus during 20 min ( Fig. 3(e 
),
Scientific RepoRts | 7: 4336 | DOI:10.1038/s41598-017-04499-7 inset). As in another report 40, 41 , the transcription-regulatory activity of GRα was retained after tagging with such fluorescent proteins.
Typical autocorrelation and cross-correlation curves of FCCS conducted in the cytoplasm and nucleus are shown in Fig. 3 . As a negative control, U2OS cells were cotransfected independently with mCherry 2 -and EGFP-encoding plasmids, and FCCS was carried out in the absence ( Fig. 3(a) ) and presence of Dex ( Fig. 3(b) ). The cross-correlation amplitude was not observed in either case, pointing to no unknown interaction between EGFP and mCherry 2 . As a positive control, U2OS cells were cotransfected with p50-mCherry 2 /nuclear localization signal (NLS)-encoding and p50-EGFP/NLS-encoding plasmids ( Fig. S1M and N) , which are coexpressed in the nucleus as the proteins of interest ( Fig. 3(c) , inset). The p50 protein is a subunit of NF-kB, and proteins of this family associate as a homo-(p50-p50) and heterodimer (p50-p65). Endogenous expression of p50 was not detected in U2OS cells (Figs S2B and S15B). A high cross-correlation amplitude was observed ( Fig. 3(c) ) between the p50-mCherry 2 /NLS and p50-EGFP/NLS in FCCS measurement. Low cross-correlation amplitude of mCherry 2 -hGRα and EGFP-hGRα was observed in the absence of Dex ( Fig. 3(d) ) in the cytoplasm. In contrast, a . Determination of in vitro K d of GRα mutants using the FCCS-microwell system. Typical auto-and cross-correlation curves constructed by measurements in microwells after lysis of U2OS cells coexpressing EGFP-hGRα mutants and mCherry 2 -hGRα mutants in the presence of Dex. The green dashed line, red dotted line, and black solid line denote the autocorrelation of the green channel [G G (τ)], autocorrelation of the red channel [G R (τ)], and cross-correlation [G C (τ)], respectively. The insets show an enlarged graph of the crosscorrelation curve and fitting residuals of autocorrelation and cross-correlation curves. LSM images of U2OS cells coexpressing EGFP-hGRα mutants and mCherry 2 -hGRα mutants before and after cell lysis in a microwell for the C421G mutant (a) and A458T mutant (b). The scale bar is 20 μm. FCCS was performed in a microwell after cell lysis for the C421G mutant (c) and A458T mutant (d) in the presence of Dex. (e, f) Results of K d determination using a scatter plot and linear regression. The plots represent the square of the concentration of the monomeric hGRα versus the concentration of the dimer of hGRα. The solid red line shows the linear fit. The slope indicates K d . (e) The C421G mutant in the presence of Dex. (f) The A458T mutant in the presence of Dex. (g) A summary of in vitro K d values determined using the FCCS-microwell system. WT: wild type, C421G: the C421G mutant, A458T: the A458T mutant. Statistical analysis was based on ANOVA (**p < 0.01) (h) A schematic diagram of mCherry 2 -and EGFP-fused constructs of mutated hGR, C421G (DNA-binding-deficient mutant) and A458T (homodimerization-deficient mutant). The RCA of the interaction between EGFP-hGRα and mCherry 2 -hGRα in the living cells show similar tendencies against concentration ratio of mCherry 2 -hGRα and EGFP-hGRα ( Fig. S5A and B ), and was significantly higher than that of the coexpression of EGFP and mCherry 2 , indicating that FCCS could detect the GRα homodimerization in the living cells as well as in vitro (Fig. S5C ). K d of p50-mCherry 2 /NLS and p50-EGFP/NLS in the nucleus was found to be 2.20 μM ( Fig. 3(h) ). This result was consistent with another report on the micromolar range of K d for p50 homodimerization in vitro 42 . K d values of mCherry 2 -hGRα and EGFP-hGRα were found to be 7.40 μM in the absence of Dex in the cytoplasm ( Fig. 3 (f)) and 3.00 μM in the presence of Dex in the nucleus ( Fig. 3 (g)). K d was significantly (p < 0.01) lower in the presence of Dex than in its absence. These quantitative results suggested that WT GRα has a tendency toward homodimerization in the presence of Dex and toward monomerization in the absence of Dex.
To create a model of inhibition of GRα homodimerization, cells coexpressing mCherry 2 -hGRα and EGFP-hGRα were incubated with RU486 (mifepristone), which is an inhibitor of transcription-regulatory activity 43, 44 . In the inset of Fig. 4(b) , mCherry 2 -hGRα and EGFP-hGRα relocated to the nucleus after the addition of RU486, as with Dex. A negligible cross-correlation amplitude was occasionally observed ( Fig. 4(b) ), but the obtained K d value was 7.20 μM ( Fig. 4(c) ), which was the same as that of the WT in the absence of Dex (7.40 μM) in the cytoplasm, suggesting that WT GRα had a tendency toward the monomer form during treatment with RU486. However, at the high concentration (1 μM) of RU486, the homodimerization of GRα in the presence of RU486 has been reported after a number and brightness analysis in vivo 22 . K d value was also determined at 1 μM RU486 treatment. Low cross-correlation amplitude was observed ( Fig. S6A ) and K d value was 8.59 μM ( Fig. S6B ), which was similar to that in the presence of 100 nM RU486. The diffusion constant of EGFP-hGRα was determined by the autocorrelation function fitted to the two-component model, which also provided the dynamic properties of GRα before and after the addition of Dex. Figure S7 shows scatter plots of diffusion constants versus apparent fraction percentages of EGFP-hGRα in the absence and presence of Dex. The diffusion constant of the slow component decreased in the presence of Dex compared with its absence (Fig. S7 ). Overall, these results indicated a slowdown of GRα mobility in the presence of Dex for the complex formation with associated molecules and for interaction with DNA. Furthermore, the effect of the antagonist (RU486) on the diffusion of GRα was assessed in FCCS experiments ( Fig. 4(d) ). The diffusion constant of the fast component of WT GRα was not affected by the presence of RU486, in contrast to Dex. In addition, the diffusion constant of the slow component in the presence of RU486 became larger than that during Dex treatment, suggesting that the molecule became fast moving ( Fig. 4(d) , downward triangle). These results indicated dissociation of the initial complex and/or an unstable complex formation of GRα with the GRE in the presence of RU486, in agreement with our previous report 2 .
FCCS analysis of the mutants of hGRα in the nucleus.
To confirm the homodimerization of GRα in living cells, U2OS cells were transiently cotransfected with mCherry 2 -hGRα/C421G and EGFP-hGRα/ C421G ( Fig. S1C and D) , mCherry 2 -hGRα/A458T and EGFP-hGRα/A458T ( Fig. S1E and F) , and with mCherry 2 -hGRα/C421G-A458T and EGFP-hGRα/C421G-A458T ( Fig. S1G and H) . According to the insets of Fig. 5 (a), (b), and (c), C421G, A458T, and C421G-A458T were translocated to the nucleus after the addition of Dex as WT GRα. It should be noted that there was no difference in the static laser scanning microscopy (LSM) imaging method between the WT and mutants. The cross-correlation amplitude was observed in the C421G mutant ( Fig. 5(a) ) and A458T mutant ( Fig. 5(b) ) after the addition of Dex. In contrast, the C421G-A458T ( Fig. 5 (c)) mutant showed low cross-correlation amplitude in the nucleus after the addition of Dex. K d values of mCherry 2and EGFP-fused C421G, A458T, and C421G-A458T were calculated from each slope: 3.51, 6.11, and 5.84 μM, respectively ( Fig. 5(d )-(f)). These results suggested that the tendencies of the A458T and C421G-A458T mutants toward a monomer form were stronger than that of the WT (3.00 μM). In contrast, the tendency of C421G to homodimerization was similar to that of the WT. The scaffold effect of DNA for GR homodimerization was not significantly observed in vivo, which was observed in vitro experiments. Next, the diffusion properties of GRα mutants were analyzed in the nucleus of a live cell. The autocorrelation functions of EGFP-hGRα/C421G, EGFP-hGRα/A458T, and EGFP-hGRα/C421G-A458T mutants in the nucleus were analyzed by two-component fitting. Comparative analysis of the diffusion constants of WT GRα and its mutants are shown in scatter plots in Fig. S8 . The fast component of each mutant was not affected by the addition of Dex. In contrast, the diffusion constants of the slow component increased after the addition of Dex, in comparison with the WT (Fig. S8 ).
FCCS analysis of NLS region-mutated hGRα in the cytoplasm.
To test whether the GRα homodimerizes in the cytoplasm, we constructed mCherry 2 -and EGFP-fused nuclear localization signal 1-mutated (∆NLS) hGRα that did not relocate to the nucleus, and A458T-∆NLS mutants that neither formed homodimers nor relocated to the nucleus. U2OS cells were transiently cotransfected with plasmids encoding mCherry 2 -hGRα/∆NLS and EGFP-hGRα/∆NLS ( Fig. S1I and J) and mCherry 2 -hGRα/A458T-∆NLS and EGFP-hGRα/ A458T-∆NLS ( Fig. S1K and L) . As a positive control, FCCS was conducted on p50-mCherry 2 and p50-EGFP ( Fig. S1O and P), which were coexpressed in the cytoplasm ( Fig. 6 (a), inset). K d values were found to be 1.77 μM for p50-mCherry 2 and p50-EGFP in the cytoplasm ( Fig. 6(e) ). According to the insets of Fig. 6 (c) and (d), the mCherry 2 -and EGFP-fused ∆NLS mutant and the A458T-∆NLS mutant were localized to the cytoplasm in the presence of Dex. FCCS was performed in the cytoplasm in the absence ( Fig. 6(b) ) and presence of Dex (Fig. 6(g) ), respectively. Our results suggested that in the condition without Dex stimulation, GRα/∆NLS had a lesser tendency toward monomerization but also formed a homodimer in the cytoplasm, whereas the proportion of GRα homodimers tended to increase after the addition of Dex. To confirm the GRα homodimerization in the cytoplasm, FCCS of the homodimerization-deficient mutant, mCherry 2 -hGRα/ A458T-∆NLS, and EGFP-hGRα/A458T-∆NLS was performed in the presence of Dex ( Fig. 6(d) ). Very low cross-correlation amplitude was only observed. K d was found to be 8.52 μM ( Fig. 6(h) ), which was higher than that of EGFP-hGRα/ΔNLS and mCherry 2 -hGRα/ΔNLS in the absence and presence of Dex. Figure 7 (a) and (b) show summaries of the obtained K d values in living cells. This evidence pointed to the presence of the homodimer of GRα in the cytoplasm. The diffusion properties of these mutants were analyzed in the cytoplasm of living cells. Comparative analysis of the diffusion constants of the WT and mutants is shown in scatter plots in Fig. S9 . In the cytoplasm, the fast and slow components of each mutant were not affected by the addition of Dex. This observation was suggestive of formation of the complex between the NLS-mutated GRα and other cytoplasmic proteins, same as WT GRα. Taken together, these results supported the hypothesis that GRα can homodimerize in the cytoplasm in the presence of Dex.
Discussion
As mentioned in the introduction, there are a number of controversial issues regarding homodimerization of GRα. Generally, steroid receptors regulate transcription via two main pathways. In the first one, two molecules of steroid receptors bind to DNA in a cooperative manner; thus, binding of the first molecule accelerates the binding of the second molecule sequentially, forming a homodimer via a dimerization interface (monomer pathway). In the other pathway, preformed homodimers of steroid receptors bind to DNA (dimer pathway) 22, [45] [46] [47] [48] . In the case of GRα, it is still a subject of debate when and where the homodimerization takes place and whether it proceeds through the monomer pathway 10, 15, 16, 49 or the dimer pathway 11, [17] [18] [19] [20] [21] 50 . Our observations and other studies indicate that the transition time from the cytoplasm to the nucleus ranges from 10 to 60 min after the addition of Dex 2, 51, 52 . We can hypothesize a dynamic monomer pathway where GRα is in equilibrium between monomeric and homodimeric forms in the cytoplasm as well as in the nucleus during this rather long transition time, and where GRα relocates to the nucleus as a monomer and forms the GRα homodimer before DNA binding in the nucleus (Fig. 8 ).
K d of homodimerization of the WT and mutants of GRα in vitro was confirmed using the FCCS-microwell system. The in vitro K d of WT GRα was determined to be 416 and 139 nM in the absence and presence of Dex, respectively ( Fig. 1(e) and (f) ). This result is in good agreement with K d obtained in the brightness analysis using the FCS-microwell system 14 . Moreover, K d for homodimerization of the C421G mutant and A458T mutant in vitro was 244 and 379 nM, respectively, in the presence of Dex (Fig. 2(e) and (f) ). The tendencies of K d values of the WT relative to the mutants in vitro were similar to those in living cells (Figs 2(g) and 7(a) ). On the other hand, the absolute values of K d in vitro were lower than those in living cells. This finding suggests that there are some mechanisms that keep the monomer form of hGRα in living cells.
Next, K d values of hGRα homodimerization were determined by FCCS in living cells. K d of WT GRα was 7.40 μM in the cytoplasm in the absence of Dex ( Fig. 3(f) ) and 3.00 μM in the nucleus in the presence of Dex ( Fig. 3(g) ), indicating that GRα has a tendency toward homodimerization in the nucleus (Fig. 8(a) , vii, viii). By contrast, K d of the GRα homodimerization was in the nanomolar range in vitro (Fig. 2(g) ). Our findings indicate that GRα forms a homodimer in the nucleus in the presence of Dex; however, judging by the rather high value of K d (3.00 μM), GRα in equilibrium is distributed between the monomeric form and homodimeric form ( Fig. 8(a) , v↔vii). The presence of both monomeric and homodimeric forms at the rather high value of K d than expression level of hGRα in the living cells (300 nM to 2300 nM for WT hGRα) may enable formation of complex with other nuclear receptors such as mineralocorticoid receptor. K d of the A458T mutant (homodimerization-deficient mutant 39 ) was 6.11 μM in the presence of Dex ( Fig. 5(e) ), which is higher than that of WT GRα in the presence of Dex (3.00 μM) and lower than that of WT GRα in the absence of Dex (7.40 μM). The tendency of the A458T Figure 7 . A summary of the dissociation constants (K d ) of the WT and mutants before and after addition of ligands. The bars indicate the dissociation constants, K d . (a) Before addition of Dex, the dissociation constant (K d ) of the WT was 7.40 μM in the cytoplasm, and after addition of Dex the K d values of the WT, C421G, A458T, and C421G-A458T were 3.00, 3.51, 6.11, and 5.84 μM, respectively, in the nucleus. K d of the control p50-p50 in the nucleus was 2.20 μM. (b) Before addition of Dex, K d of ∆NLS was 2.28 μM and after addition of Dex, K d values of the ∆NLS and A458T-∆NLS mutants in the cytoplasm were 2.19 and 8.52 μM, respectively. K d of the p50-p50 dimer in the cytoplasm was 1.77 μM. The data are presented as mean ± SD. Statistical analysis was based on ANOVA (*p < 0.05, **p < 0.01). mutant toward the monomer was stronger than that of WT GRα in the presence of Dex ( Fig. 7(a) ). These results indicate that the A458T mutation in GRα impairs the homodimerization in living cells, but some part of the A458T mutant forms a homodimer. This finding is consistent with the literature data, which suggest that the A458T mutant can form a homodimer 53 .
In the present study, effects of RU486 on the process of hGRα homodimerization were also examined. It has been demonstrated that RU486 works as an antagonist of transcription-regulatory activity 43, 44 , but some studies revealed its partial agonist behavior for transcription of GRα 22, 54-56 . K d of WT GRα was 7.20 μM and 8.59 μM in the presence of 100 nM and 1000 nM RU486, respectively (Figs 4(c) and S6); these values are the similar to that of the WT in the cytoplasm in the absence of Dex (7.40 μM). This observation suggests that a lack of homodimer of GRα inhibits the transcriptional-regulatory activity. In contrast, homodimerization of GRα in the presence of RU486 has been reported after a number and brightness analysis in vivo 22 . This discrepancy is unclear, but may be due to the different cell line with the expression of GRα in the living cells.
Our results also answered the question whether binding of GRα to DNA is necessary for homodimerization. The C421G mutant, which cannot associate with a GRE, does not have a transcription-regulatory activity 38 . K d of the C421G-A458T double mutant of GRα was 5.84 μM in the presence of Dex ( Fig. 5(f) ); this value was higher than that of the C421G mutant but was the same as that of A458T mutant in the presence of Dex. Some studies suggested that GRα homodimerizes only after DNA binding 10, 16, 49 . In contrast, earlier studies had revealed GRα homodimerization in solution, independently of DNA binding 14, 23 . Our results support GRα homodimerization before DNA binding ( Fig. 8(a) , vii) according to FCCS measurement of the DNA-binding-deficient mutant (C421G) and a double mutant with DNA-binding and dimerization deficiencies (C421G-A458T; Fig. 7(a) ). To reconcile these discrepancies, however, a more dynamic view of hGRα is needed. K d of the A458T mutant and C421G-A458T mutant was higher than that of C421G and lower than those of the WT (without Dex) ( Fig. 7(a) ). Thus, these results suggest that C421G-A458T and A458T has a tendency to be in the monomeric form but also in the homodimeric form. Moreover, different diffusion properties were observed between A458T and C421G-A458T (Fig. S8E) . The diffusion constant of the slow component of the C421G-A458T mutant was greater (faster) than that of A458T in the presence of Dex (Fig. S8E) . This finding suggests that C421G-A458T cannot bind to a GRE but A458T can do so as a monomer (Fig. 8(a) , v→vi). This result seems to support the finding that monomers of WT GRα and of the A458T mutant have a weak (ii) hGRα is activated after ligand binding. Activated hGRα in the cytoplasm is in equilibrium between a monomer and dimer (iii) but transport of dimeric hGRα is unclear. (iv) Activated monomer hGRα relocates into the nucleus and is in both the free state (v) and monomer form, which can bind to a GRE as an unstable complex (vi). (vii) hGRα further dimerizes in the nucleus. (viii) The preformed dimer of hGRα associates with the GRE and other transcription factors. The dimer and monomer are not only distributed in the cytoplasm but also in the nucleus even after ligand binding; however, transport of hGRα is carried out in the monomeric form of hGRα. The concentration of hGRα in the nucleus can be controlled by changing the K d of hGRα and GRE in the nucleus. (b) The static dimer pathway: (i) hGRα is localized to the cytoplasm as a complex or in free form in the uninduced state. (ii) hGRα is activated after ligand binding. Activated hGRα exists in the cytoplasm as a dimer (iii). (iv) In the dimer form, hGRα is translocated. The preformed dimer (v) of hGRα associates with a GRE and transcription factors (vi). The dimer of hGRα is distributed in both the cytoplasm and nucleus, but the monomer is found only in the cytoplasm. hGRα is transported in the dimer form. The concentration of hGRα in the nucleus can be controlled by the activity and functions of the NPC. hGRα: human glucocorticoid receptor α, hsp90: heat shock protein 90, GREs: glucocorticoid response elements, NM: nuclear membrane, NPC: nuclear pore complex transcription-regulatory activity in a reporter assay involving a palindromic GRE sequence 57 . These data suggest that an initial and/or unstable complex of the A458T GRα mutant with the GRE forms in the presence of Dex ( Fig. 8(a) , v→vi), in line with our previous reports 2, 51 .
To test whether GRα homodimerizes in the cytoplasm, the K d values of ∆NLS and A458T-∆NLS mutants of GRα in the presence of Dex were determined by FCCS. These mutants were expected to be incapable of translocation to the nucleus or formation of homodimers in the presence of Dex. We found the K d values of ∆NLS to be 2.28 μM in the absence of Dex (Fig. 6(f) ) and 2.19 μM in its presence ( Fig. 6(g) ). These data are suggestive of the presence of a preformed homodimer in the unliganded state in the cytoplasm because K d was lower than that of the WT GRα in the absence of Dex. It is possible that the mutation of NLS elicits a conformational change and/or a big change in electrostatic properties of the GRα moieties that facilitates formation of homodimers. In contrast, K d of the A458T-∆NLS mutant was estimated to be 8.52 μM (Fig. 6(h) ). These findings reinforce the idea that cytoplasmic homodimerization of GRα takes place at the initial stage of stimulation ( Fig. 8(a) , ii→iii) in agreement with other studies 17, 23 . As expected, the tendency of the A458T-ΔNLS mutant toward the monomeric state is stronger than that of the ∆NLS mutant after the addition of Dex. However, the results do not support the notion that GRα relocates into the nucleus in homodimeric form because K d is still in the micromolar range, i.e., much higher than the in vitro K d values. It can thus be reasonably assumed that the K d value should be in the nanomolar concentration range if all of GRα form a homodimer after ligand binding. Therefore, our results do not support the translocation of GRα from the cytoplasm to the nucleus as a homodimer (Fig. 8(a) , iii and iv) although a recent study showed the translocation of GRα in the homodimer form 17 . Further experiments, such as single-molecule tracking or multipoint FCCS need to be carried out to uncover the details of quaternary structure during the transport through the nuclear pore; we would like to do these experiments in a future study.
There may be a static dimer pathway, where GRα is transported from the cytoplasm to the nucleus in the homodimeric form. Thus, the concentration of GRα in the nucleus can be controlled by activity of the nuclear pore complex ( Fig. 8(b) , NPC). In contrast, our results support the existence of a dynamic monomer pathway, in which the concentration of GRα in the nucleus can be controlled by changes in the binding affinity between GRα and a GRE ( Fig. 8(a) ). Our findings appear to be substantiated by a report on a mineralocorticoid receptor (MR) indicating that only homodimers that form in the nucleus (after activation by ligand binding) can be transcriptionally active, whereas homodimers in the cytoplasm do not have the ability to relocate to the nucleus or regulate gene expression 45 .
In conclusion, our quantitative data show homodimerization of hGRα in the nucleus and cytoplasm of living cells. To our knowledge, this is the first report of quantitative differences between homodimerization of WT GRα and homodimerization of its mutants on the basis of dissociation constants. The evidence obtained in this study suggests that DNA binding is not necessary for GRα homodimerization in the nucleus in vivo. Our findings should advance the understanding of the homodimerization, DNA binding, and dynamics of GRα in living cells.
Materials and Methods
Chemicals and antibodies. Dexamethasone (Dex) and RU486 were purchased from Sigma-Aldrich.
McCoy's 5A modified medium and charcoal-stripped fetal bovine serum were purchased from GIBCO (Invitrogen). A mouse monoclonal anti-GR antibody (ab9568) was acquired from Abcam; a monoclonal anti-GFP (mouse IgG1-K) antibody (GF200) from Nacalai Tesque, Inc.; anti-actin clone C4 (mouse monoclonal) antibody from Millipore; an anti-NF-κBp50 (D-6) sc-166588 mouse monoclonal IgG1 antibody from Santa Cruz Biotechnology, and the alkaline phosphatase-conjugated anti-mouse antibody was purchased from Biosource TM .
Plasmids. All schematic representations of the plasmids are shown in Fig. S1 . The plasmids encoding human glucocorticoid receptor α (hGRα) fused with EGFP, its mutants A458T and C421G were described elsewhere 2 . The pEGFP-hGRα/C421G-A458T was constructed by insertion of the fragment amplified from DNA with the A458T mutation 2 into pEGFP-hGRα/C421G as a vector with restriction enzymes Esp3I and ClaI. For ∆NLS mutation (K494A, K495A, and K496A), a first-step PCR was performed using the following primers:
Forward-1: 5′-gggtccccaggtaaagagacgaa-3′ and Reverse-1: 5′-ccttttatggcggcggctgtttttcgagcttc-3′ and Forward-2: 5′-cgaaaaacagccgccgccataaaaggaattcag-3′ and Reverse-2: 5′-agaaacatccaggagtactgcagtaggg-3′ with pEGFP-hGRα and pEGFP-hGRα/A458T as a template. Then the first-step PCR products were mixed as a template, and second-step PCR was performed with the above forward-1 and reverse-2 primers. The second-step PCR product was digested with Esp3I and PstI, and ligated into pEGFP-hGRα as a vector that was digested with the same restriction enzymes.
To construct the mCherry tandem dimer (mCherry 2 )-fused hGRα, the fragment encoding EGFP was swapped for the fragment encoding mCherry 2 by digestion with AgeI and Bsp1407I and ligation with the "Mighty mix" DNA ligation kit (Takara, Japan). To construct the mCherry 2 -fused hGRα mutants (C421G, A458T, C421G-A458T, ∆NLS, and A458T-∆NLS), the hGRα in pmCherry 2 -hGRα was swapped for the hGRα containing each mutation with ScaI and Bsp1407I and ligation with the "Mighty mix" DNA ligation kit.
As a positive control, we used the well-known p50 protein, a subunit of NF-κB. We constructed a plasmid encoding the IPT (immunoglobulin-like plexin transcription factor) domain of p50 fused with the N terminus of mCherry 2 or EGFP (Fig. S10 ). For localization of p50 to the nucleus, p50-mCherry 2 /NLS and p50-EGFP/ NLS were constructed. The SV40 large T antigen NLS (Pro-Lys-Lys-Lys-Arg-Lys-Gly) fused with the C-terminal mCherry 2 or EGFP and the p50 fragment flanked by NheI and AgeI sites were inserted into the N-terminal pmCherry 2 /NLS or pEGFP/NLS, then digested at the same restriction sites. As a negative control, we used a plasmid encoding mCherry 2 and EGFP.
Cell culture and transient transfection. U2OS cells were maintained in a humidified atmosphere containing 5% CO 2 at 37 °C in McCoy's 5A modified medium supplemented with 10% charcoal-stripped fetal bovine serum, 100 U/mL penicillin G and 100 μg/mL streptomycin. For FCCS, U2OS cells were plated on a Lab-TeK ® 8-well chamber cover glass (Nunc TM ) and cotransfected with different fusion constructs where the ratio of the amounts of the two plasmids was kept at 2:1 (200 ng/well pmCherry 2 -hGRα and 100 ng/well pEGFP-hGRα) using Optifect TM (Invitrogen). After 16 hrs of transfection, Dex or RU486 was added to each well at a final concentration of 100 nM with further incubation for 20 min at 37 °C. Western blotting. One day before transient transfection, U2OS cells (10 5 /well) were seeded on a 6-well Nunclon TM ∆ chamber (Nalge Nunc International). Cells were transiently transfected with the transfection reagent (mock) alone or with 1 μg/well pEGFP-hGRα, its mutants, or p50-EGFP using Lipofectamine TM 2000. After 4 hrs of transfection, the medium was replaced with a fresh one. Twenty-four hours after transfection, cells were washed with ice-cold PBS, trypsinized, collected in PBS containing trypsin inhibitor 4-[2-aminoethyl]benzenesulfonyl fluoride hydrochloride (Sigma-Aldrich), and centrifuged. The cell pellets were lysed in CelLytic TM M lysis buffer (Sigma-Aldrich) supplemented with 1% protease inhibitor cocktail (Sigma-Aldrich). The homogenates were centrifuged (15000 rpm, 4 °C) for 10 min, and the cell lysates were collected. The lysates were solubilized with 2 × Laemmli sample buffer (Nacalai Tesque), heat denatured at 65 °C for 15 min, electrophoresed in a precast 7.5% polyacrylamide gel (ePAGEL, ATTO), and then transferred onto a PVDF membrane (Bio-Rad Laboratories, Hercules, CA). The membranes were blocked overnight in 5% skim milk and washed three times in PBST buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , pH 7.4, 0.05% Tween 20) at room temperature and incubated with the primary antibodies: anti-GR, anti-GFP, anti-actin, and anti-NF-κB p50 (1:1000 dilution in "Can Get Signal" Solution I; TOYOBO) for 1 hr at room temperature. After three washes in PBST, the membranes were incubated with an alkaline phosphatase-conjugated anti-mouse IgG antibody (secondary antibody, 1:1000 dilution in "Can Get Signal" solution II; TOYOBO) for 1 hr at room temperature. Then, the membranes were washed three times with PBST and reacted with an alkaline phosphatase substrate (SIGMA FAST TM BCIP ® /NBT) solution.
Microscopy and FCCS. Live-cell fluorescence imaging and FCCS measurements were performed by a LSM 510-ConfoCor3 (Carl Zeiss), which contained Ar + laser and He-Ne laser, a water immersion objective (C-Apochromat, 40x, 1.2NA; Carl Zeiss), and two avalanche photodiodes. This setup was used both for FCCS and LSM imaging. The pinhole diameter was adjusted to 70 μm. EGFP and mCherry were excited by the 488-nm (15 μW) and 594-nm (8 μW) lasers, respectively. The emission signals were split by a dichroic mirror (600-nm beam splitter) and detected at 505-540 nm for EGFP and at 615-680 nm for mCherry. FCCS was performed 10 times with duration of 5 s before and 20 min after addition of the indicated ligands. Data analysis. FCCS data were analyzed by AIM software (Carl Zeiss). The autocorrelation functions from the green and red channels, G G (τ) and G R (τ), and the cross-correlation function, G C (τ), were computed as follows:
where τ denotes the delay time; I G and I R are the fluorescent intensity of the green and red channels, respectively; and G G (τ), G R (τ), and G C (τ) denote the autocorrelation functions of green, red channels and cross-correlation function, respectively. The acquired auto-and cross-correlation functions were fitted to a two-component model 58 : where F triplet is the average fraction of triplet state molecules, τ triplet is the triplet relaxation time, F fast and F slow are the fractions of the fast and slow components, respectively, and τ fast and τ slow are the diffusion times of the fast and slow components, respectively. For cross-correlation fitting, the triplet was not used. N is the average number of fluorescent particles in the excitation-detection volume defined by ω 1 and ω 2 which are a radius of the short and long axis of the confocal volume, and s is the structural parameter representing the ratio s = ω 2 /ω 1 
The volume elements V are calculated according to
The apparent total numbers of autocorrelation particles N G and N R and of complex cross-correlated particles N C are given in the case which brightness of fluorescent protein is homogenous by
When N G and N R are constant, G C (0) is directly proportional to N C . The backgrounds of the resulting number of particles were corrected by subtracting autofluorescence intensity of mock-transfected U2OS cells, as follows 59 :
Then,
Diffusion constants of the samples were calculated from the ratio of the diffusion constant of rhodamine 6 G (D Rh6G ; 414 μm 2 /s) and diffusion time τ R6G and τ Sample
60
.
The apparent concentration of each fluorescent protein was calculated with A (Avogadro's number) as shown below:
i corrected i corrected i , ,
C corrected C corrected C , ,
In actual measurement of EGFP-hGRα and mCh 2 -hGRα, monomer, homo-color dimer and hetero-color dimer were present in the living cells and lysate. The particle brightness of homo-color dimer was twice higher than that of monomer and hetero-color dimer. The square of average brightness of monomer, hetero-color dimer and homo-color dimer was contributed to the amplitude of autocorrelation functions. Therefore, their concentrations were calculated using relative values of particle brightness of EGFP-hGRα and mCh 2 -hGRα against EGFP and mCherry 2 co-expression sample (See supplemental information).
Determination of K d . The dissociation constant K d was determined using the following equations: and hetero-color dimer [RG] were separately determined. According to the simulation result, the measured K d values were completely matched to the given K d values by the K d calculation method with the concentration of homo-color dimer, but were not matched without its consideration (Fig. S14 ). The relative cross amplitudes (RCA) in vitro and in vivo were significantly higher than that of coexpression of EGFP and mCherry 2 as a negative control. Moreover, fold change of RCA values against negative control was over 5.6 for in vitro experiments and 17 for in vivo experiments ( Figs S4 and S5 ), suggesting that the background cross-correlation amplitude, such as cross-talk signal is not dramatically affected to cross-correlation amplitude of interactions of EGFP-hGRα and mCh 2 ) was generated with a line of best fit, and the K d was calculated from the slope of the regression line 30, 32 . All data points were strongly correlated between the square of the concentration of monomeric GR and the concentration of dimeric GR (Fig. S13 ).
Determination of in vitro K d by FCCS-microwell system. U2OS cells were cotransfected with 2 μg pmCherry 2 -hGRα and 1 μg pEGFP-hGRα using ViaFect TM (Promega). The culture method for microwell and extraction method of hGRα from the nucleus were described previously 14 . The optical setup for FCCS was the same as for in vivo FCCS. The power of 488-nm and 594-nm lasers was 15 and 12 μW, respectively. The data analysis and computation of K d values of hGRα were the same as for in vivo FCCS.
